| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | AK3 |
| Uniprot No | Q9UIJ7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-227aa |
| 氨基酸序列 | Adenylate kinase 3 alpha-like 1; Adenylate kinase 3; Adenylate kinase 3, formerly; adenylate kinase 6, adenylate kinase 3 like 1; AK 3; AK3; AK3, formerly; AK3L1; AK4; AK4, mouse, homolog of; AK6; AKL3L; AKL3L1; FIX; GTP:AMP phosphotransferase; GTP:AMP phosphotransferase, mitochondrial; KAD3_HUMAN; mitochondrial; OTTHUMP00000021015; OTTHUMP00000021016; RP11 6J24.4 |
| 预测分子量 | 32.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于AK3重组蛋白的模拟参考文献示例(注：以下内容为虚构，仅用于演示格式，实际引用请查询真实数据库)：
---
1. **文献名称**：*Recombinant Expression and Functional Characterization of Adenylate Kinase 3 in Escherichia coli*
**作者**：Zhang L., Wang Y., et al.
**摘要**：本研究报道了人源AK3基因在大肠杆菌系统中的重组表达与纯化，通过酶动力学分析揭示了AK3在ATP/ADP代谢中的特异性催化活性，并探讨其在线粒体能量稳态中的潜在作用。
2. **文献名称**：*Structural Insights into Mitochondrial AK3 by X-ray Crystallography*
**作者**：Smith J.R., Tanaka M., et al.
**摘要**：利用X射线晶体学解析了重组AK3蛋白的三维结构，揭示了其独特的底物结合域构象，为理解AK3与其他腺苷酸激酶亚型的差异提供了结构基础。
3. **文献名称**：*AK3 Deficiency and Compensatory Mechanisms in Cellular Energy Metabolism*
**作者**：Chen H., Kim S., et al.
**摘要**：通过构建AK3基因敲除细胞模型，结合重组AK3蛋白回补实验，证实AK3缺失导致线粒体ATP转运效率下降，并激活AMPK通路以维持能量平衡。
4. **文献名称**：*High-Yield Production of Recombinant AK3 in Mammalian Expression Systems for Drug Screening*
**作者**：Gupta R., Müller P., et al.
**摘要**：优化哺乳动物细胞表达系统实现AK3的高效分泌表达，并应用于靶向代谢疾病的小分子抑制剂筛选，验证了重组AK3在药物开发中的应用潜力。
---
**提示**：实际研究中请通过PubMed、Web of Science或Google Scholar等平台检索真实文献，使用关键词如“AK3 recombinant protein”、“adenylate kinase 3 expression”等。
Adenylate kinase 3 (AK3), also known as AK3 mitochondrial, is a member of the adenylate kinase family that plays a critical role in cellular energy metabolism. Located within the mitochondrial matrix, AK3 facilitates the reversible transfer of phosphate groups between nucleotides, primarily catalyzing the conversion of GTP and AMP to GDP and ADP. This reaction contributes to maintaining nucleotide balance and energy homeostasis, particularly in tissues with high energy demands such as the liver, heart, and skeletal muscle. Unlike other adenylate kinase isoforms, AK3’s substrate specificity for GTP instead of ATP reflects its unique adaptation to mitochondrial metabolic pathways.
The recombinant AK3 protein is produced using genetic engineering techniques, typically through expression in bacterial or eukaryotic systems. Its recombinant form allows researchers to study the enzyme’s structure, kinetics, and interactions in vitro, bypassing challenges associated with isolating it from native tissues. Structural studies have revealed conserved motifs critical for nucleotide binding and catalytic activity, offering insights into its regulatory mechanisms. Dysregulation of AK3 has been implicated in mitochondrial disorders, neurodegenerative diseases, and cancer, highlighting its potential as a therapeutic target or biomarker.
Research on recombinant AK3 has advanced understanding of mitochondrial bioenergetics, nucleotide metabolism, and cellular stress responses. It also serves as a tool for drug screening and mechanistic studies in pathologies linked to energy dysregulation. Despite progress, questions remain about its tissue-specific roles and post-translational modifications. Ongoing studies aim to unravel its broader biological significance beyond energy metabolism, including potential involvement in apoptosis and redox signaling.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
